Background Macro creatine kinase type 1 (MCK1) may be the cause of elevated total serum CK activity, which can lead to diagnostic confusion. There is evidence that this problem is poorly recognized perhaps due to a lack of information on its prevalence. Precipitation with polyethylene glycol (PEG) has been described for the detection of MCK1 but has not been fully evaluated.
Introduction
Macro-creatine kinase type 1(MCK1) is a complex of CK with an immunoglobulin which retains enzymic activity in laboratory assays. MCK1 can be the cause of elevated CK results but it is not of pathological signi¢cance 1--4 and is one of a number of analyte-antibody complexes which can result in diagnostic confusion and lead to unnecessary further investigation, inappropriate treatment and concern for patient and clinician. 1--5 It is important, therefore, to identify the presence of MCK1 when it is the cause of increased serum total CK activity. A further high molecular mass form of CK, MCK2, is probably the oligomeric, mito-chondrial form of the enzyme and has been detected in the serum of patients with extensive tissue breakdown, particularly malignancy. 1 MCK2 is rarely the cause of elevated total CK activity in serum. 1 A simple screening test for macro-analytes based on precipitation of immunoglobulins and immunoglobulin complexes by polyethylene glycol (PEG) has been extensively evaluated for macroprolactin 5 and macroamylase 6 and has recently been applied to other commonly measured enzymes including CK. 7 However, since up to 60% of uncomplexed, normal CK appears to be precipitated, PEG precipitation may not be speci¢c for MCK1, or PEG may interfere in CK assays 7 and there is little information on the sensitivity and speci¢city of r 2007 The Association for Clinical Biochemistry the PEG precipitation test in the detection of MCK1. There is evidence that MCK1 remains poorly recognised as a cause of elevated serum CK activity 7, 8 and whereas screening for hyperprolactinaemia due to macroprolactin using PEG precipitation is common practice in the UK, in our experience screening for MCK1 is rare. This may be due to the relatively low prevalence of macroCK, which has been reported to be 0.8--2.3%. 1 However, such estimates are largely derived from studies involving CK isoenzyme electrophoresis in populations with suspected acute coronary syndrome and are estimates of the overall prevalence of MCK1 in that population rather than the prevalence of MCK1 as a cause of elevated total CK activity in the population. Furthermore, the population from which routine requests for CK measurement are received has changed recently since CK and CK isoenzymes were replaced by cardiac troponins as the preferred markers for the detection of acute coronary syndromes. 9 In this study we introduced a systematic screening programme to detect elevated serum CK activity due to MCK1 based on the PEG precipitation test with con¢rmation using a classical gel ¢ltration chromatography technique (GFC). We determined the prevalence of elevated CK activity due to MCK1 in our population and compared the results of the screening programme with those from a laboratory which selected samples for testing during the clinical validation process.
We also examined some of the characteristics of the PEG precipitation test for the detection of MCK1 and investigated sensitivity and speci¢city by comparison with GFC.
Methods

Screening programme
The laboratory at Southend Hospital introduced a systematic screening procedure for MCK1 as follows. The laboratory computer was programmed to list, on a weekly basis, all patients with a serum CK result above the upper limit of the sex-related reference ranges for Caucasians (189 U/L in males and 160 U/L in females) using the Roche assay on the Modular P unit. The computer records were then searched for previous CK results on these patients and if a previous result was found which was above or within the upper quartile of the reference ranges (4148 U/L in males and 4130 U/L in females), the sample was retrieved for further investigation. PEG precipitation was employed as a screening test for MCK1 using the same technique described for the detection of macroprolactin. 10 In brief, 200 mL serum was mixed with 200 mL 250 g/L PEG (Merck, average molecular mass 6000) in water (the PEG reagent was replaced every month because it has been reported to be unstable 10 ). After mixing and centrifugation at 3000 rpm for 10 min the supernatant was removed and assayed for CK activity together with a dilution of the sample in an equal volume of TRIS/ saline bu¡er pH 7.4. If su⁄cient sample remained available, those in which the proportion of CK precipitated by PEG precipitation was in the highest quartile of all results were further examined for the presence of MCK1 by gel ¢ltration chromatography (GFC). We used a 1.6 Â 40 cm column of Sephacryl S-300 or S-100 (Pharmacia) and eluted with TRIS/ saline bu¡er pH 7.4 at a £ow rate of 0.5 mL/min and collected 25 fractions of approximately 1.5 mL. CK activity and albumin concentrations in the fractions were measured using the standard Roche assays on the Modular P unit but in the case of albumin a larger sample volume was used to compensate for the lower concentrations found in the fractions. In this chromatography system normal serum CK elutes in the same fractions as serum albumin while MCK1 elutes earlier due to its increased molecular mass. The peak of albumin serves as a convenient marker of molecular mass.
The results from this systematic screening programme were compared with those from the laboratory at Tunbridge Wells which had a di¡erent approach to screening. This involved identifying cases during validation of abnormal results and only further investigating those samples with persistently, and relatively consistently, raised CK levels for which there was no obvious clinical or biochemical explanation. Patients' notes were scrutinised if possible. The laboratory at Tunbridge Wells also received samples for investigation for MCK1 from other laboratories, irrespective of the above criteria and also used PEG precipitation with con¢rmation of the presence of MCK1 by GFC when more than 63% of the CK activity was precipitated by PEG treatment.
Investigation of PEG precipitation technique
Samples characterised as to the presence or absence of MCK1 by GFC were used to study the e¡ects of PEG concentration and of added gamma globulin (Sigma Cohn fraction II/III) on the precipitation of MCK1 and normal serum CK by PEG. In one case which showed no evidence of MCK1 on GFC the serum was treated with PEG and the supernatant was discarded. The precipitate was washed with 125 g/L PEG in TRIS/ saline bu¡er, dissolved in TRIS/saline bu¡er containing 40 g/L bovine serum albumin and subjected to GFC.
The between batch precision of the PEG precipitation technique was studied using aliquots of a pool of serum with elevated CK activity stored at À201C.
Results
Screening programme
The laboratory at Southend received 3475 CK requests during a 12-month period from December 2003 to November 2004. The major sources of these requests were; General Practitioners 48%, Renal Physicians 18% and Rheumatologists 12%. From all the requests 155 patients were identi¢ed who had two or more elevated results. The median proportion of CK activity precipitated by PEG precipitation in the samples from these patients was 36%, with 95% of values between 10 and 50% ( Figure 1) . GFC was carried out on 26 of the 39 samples with CK activity after PEG treatment in the highest quartile of results (441.5% PEG precipitable activity) and the presence of MCK1 was con¢rmed in four of these ( Figure 1 ). There was insu⁄cient serum available to carry out GFC in the remaining 13 samples. In three of the cases in which MCK1 had been con-¢rmed su⁄cient serum was available to adsorb serum IgG and IgG complexes with protein A-Sepharose (Sigma) and the reduction in CK activity (33--85%, normal o16%) indicated that the MCK1 was a CK-IgG complex. Further details of all four cases are shown in Table 1 and a report of case MP is given below.
Case report
MP was a 63-year-old lady with a history of ulcerative colitis, treated with prednisolone, and chronic obstructive pulmonary disease. She complained to her GP of pain in her ankles, calves, thighs and arms and on investigation serum CK activity was found to be 467 U/L (normal o167) and she was referred to the Rheumatology outpatient clinic. Repeat serum CK was 682 U/L and TSH was slightly elevated (7.1 IU/L) with normal fT4 (16.2 pmol/L). She complained of limb weakness, morning sti¡ness and muscle pain. Diagnoses of idiopathic in£ammatory myopathy and hypothyroid myopathy were considered and thyroxine was prescribed. Repeat CK was 795 U/L, TSH 0.17 and fT4 25.1. The thyroxine was stopped. Electromyelographic studies showed normal results of nerve conduction and repetitive nerve stimulation in the arms and legs but patchy, mild myopathic changes in proximal muscles of the right arm and leg. Repeat serum CK activity was 1025 U/L and a muscle biopsy was requested but before this could be carried out MCK 1 was serendipitously discovered in this study and shown to comprise 95% of the total serum CK activity.
The results of chromatography from MP are shown in Figure 2 . Serum CK remained elevated (821 U/L) due to MCK1 after a further two years. In all four cases in which the presence of MCK1 was con¢rmed the total CK activity was modestly but consistently increased above the upper limits of the sexrelated reference ranges and the CK remaining after PEG precipitation was less than 50% of the original. The normal, uncomplexed CK, calculated from the results of GFC, was within the reference range indicating that MCK1 was the cause of the elevated total serum CK activity. The prevalence of elevated CK activity due to MCK1 in the population screened was 2.6%. We estimated the cost of the screening programme for the 12-month period to be »2000. These costs were based on reagent costs for PEG precipitation and CK assay and the time for a Biomedical Scientist to carry out a batch of PEG precipitation tests every two weeks followed by chromatography where necessary.
In a further12-month period from December 2004 to November 2005 the PEG precipitation screening programme was modi¢ed in the light of the earlier ¢ndings and applied only to patients with serum CK activity above the upper limit of the sex-related reference ranges but less than 3000 U/L and a similarly elevated CK result previously. The cut-o¡ of 3000 U/L was chosen because MCK1 has not been reported to cause increases in serum total CK activity greater than this 1 in accordance with the experience of one of us (GL) acting as a referral laboratory for the investigation of MCK1. 213 patients were identi¢ed with the modi¢ed criteria and General Practitioners were again the major source of these requests (59%). GFC was applied to the nine cases found to have 450% PEG precipitable CK activity and the presence of MCK1 was detected in three ( Table 1 ). The prevalence of MCK1 in the population screened was 1.4%.We analysed the clinical information accompanying 101 consecutive requests. A reference to therapy with statins was most common (30% of all requests) but 15% had no clinical information.
The laboratory at Tunbridge Wells selected 11 samples for further investigation during clinical validation of results in 5 years. Seven of these were con¢rmed by GFC to contain MCK1 but in only six cases the MCK 1 was the cause of the elevated total serum CK activity. In the same period 60 requests for investigation for MCK1 were received from external sources of which 5 were shown to contain MCK1.
Investigation of the PEG precipitation technique
GFC of whole serum and the PEG precipitate ( Figure 3 ) in a case with elevated serum CK activity (1523 U/L) and no evidence of MCK1 (30% PEG precipitable CK activity) showed the presence of normal, uncomplexed CK activity in the PEG precipitate. Figure 4 shows the e¡ect of varying PEG concentration on the precipitation of normal CK and of MCK1 and Figure 5 shows the e¡ect of added gamma globulin on the precipitation of normal CK by PEG.
Over a period of 10 months aliquots of frozen pooled serum were assayed by the PEG precipitation technique. Total CK activity declined steadily during this period from 417 U/L to264 U/L but the proportion of PEG precipitable CK activity remained relatively constant, mean 19.2%, CV 18.2% (n ¼14).
Discussion
PEG precipitation is a simple and inexpensive technique which may be in use in many laboratories for macroprolactin screening. For this reason we used PEG at the concentration of 250 g/L in water used for macroprolactin screening 5 rather than 240 g/L which has been used for investigations for macroenzymes. 6, 7 It is clear from Figure 4 that such a minor di¡erence in the concentration of PEG would make little di¡erence to the amount of CK precipitated. In the precipitation of proteins, PEG acts as an inert solvent sponge, excluding proteins from the regions of the solvent occupied by the PEG and, with increasing PEG concentration, raising the e¡ective concentration of proteins until their solubility is exceeded and precipitation occurs. 11 A number of factors in£uence the solubility of proteins in solutions of PEG but proteins of large molecular size are more susceptible to precipitation. 11 When applied to serum PEG precipitation is relatively speci¢c for the precipitation of immunoglobulins and immunoglobulin complexes but our results clearly demonstrate that PEG precipitates some uncomplexed, normal CK. Although this can be minimized by lowering the PEG concentration, this reduces the e⁄ciency of precipitation of MCK1 so that it is only possible to improve the speci¢city of PEG precipitation at the expense of sensitivity. We have also demonstrated that the serum gamma globulin concentration has a modest in£uence on the precipitation of normal CK by PEG and that uncomplexed, normal CK is co-precipitated with serum globulins.We found no evidence of interference by PEG in the Roche CK assay but this should be checked with other enzyme assays. It is also noteworthy that PEG is less e¡ective in precipitating IgA 7 than IgG, and that some forms of MCK1 are CK-IgA complexes. 1 Since PEG precipitation is not speci¢c for MCK1 it is necessary to set a cut-o¡ which maximises sensitivity while minimizing the number of samples which require further investigation by a more speci¢c technique. The choice of con¢rmatory technique is between electrophoresis and GFC and the latter may have some advantage in that it utilises the same CK assay used to determine the total serum CK activity and the activity remaining after PEG precipitation. GFC also allows a quantitative estimate to be made of the proportion of total CK activity due to MCK1 and this may be important since MCK1 can co-exist with elevated uncomplexed CK activity of pathological signi¢cance. Quality assurance of the PEG precipitation procedure with frozen, pooled serum was not entirely satisfactory because the total CK activity was not stable. Commercially available quality assurance serum may be more stable and in preliminary experiments we have found that the lyophilized, bovine material from Randox shows a similar chromatography pattern and proportion of PEG precipitable CK activity to human serum but further study is required. The frequency distribution of PEG precipitable CK activity in the population under investigation (Figure 1 ) may provide a measure of quality assurance.
It is of interest that the most common reason stated on the request form for measurement of serum CK activity was related to instituting treatment with statins or monitoring treatment. This practice is advocated by the British National Formulary. In our experience modestly elevated serum CK activity due to MCK1 can lead to potentially bene¢cial therapy with statins being withheld or withdrawn 12 and this is a cause for concern.
From the experience of the laboratory at Tunbridge wells it is clear that many cases of elevated CK due to MCK 1 can be detected during the clinical validation process. This activity has been the subject of discussion recently 13 and it has been stressed that Clinical Biochemists are in a unique position of understanding the potential for analytical and pre-analytical errors. Nevertheless the only clear indications for investigation for MCK 1 are a persistently elevated serum CK with no apparent clinical cause and it is di⁄cult to detect such cases given the limited information available during clinical validation of results. It is also clear that systematic screening would detect approximately 500 cases per annum in the UK and that few of these are detected at the moment.
Conclusions
We conclude that the prevalence of elevated CK activity due to MCK 1 is approximately 2% in patients with persistently elevated serum CK. The elevated CK activity in these patients may lead to unnecessary concern for patient and physician, unnecessary further investigation and to withholding or cessation of potentially bene-¢cial treatment with statins. Clinical Biochemists should be aware of the problems caused by MCK 1 when they carry out clinical validation of results but consideration should be given to introducing a systematic screening programme based on PEG precipitation. 
